IGF1Ec expression in MG-63 human osteoblast-like osteosarcoma cells

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4259-4265

  Philippou, Anastassios ^a   Armakolas, Athanasios ^a   Panteleakou, Zacharoula ^a   Pissimissis, Nikos ^a   Nezos, Adrianos ^a   Theos, Apostolos ^a   Kaparelou, Maria ^a   Armakolas, Nikos ^a   Pneumaticos, Spyridon G ^a   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Alternative splicing; Insulin like growth factor 1; MG 63 osteosarcoma cells

Indexed keywords

INSULIN; INSULIN RECEPTOR; PEPTIDE E; SMALL INTERFERING RNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOBLAST; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ALTERNATIVE SPLICING; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOSARCOMA; PEPTIDES; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, INSULIN; RNA, SMALL INTERFERING; TRANSGENES;

EID: 84855174155     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Canalis E, McCarthy T and Centrella M: Growth factors and the regulation of bone remodeling. J Clin Invest 81: 277-281, 1988. (Pubitemid 18075217)
2. Burrow S, Andrulis IL, Pollak M and Bell RS: Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 69: 21-27, 1998. (Pubitemid 28452269)
3. Belfiore A, Frasca F, Pandini G, Sciacca L and Vigneri R: Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30: 586-623, 2009.
4. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, McCarthy CD and Gore L: A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 16: 2458-2465, 2010.
5. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA and de Bono JS: Phase I dose escalation study of the anti-insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13: 5834-5840, 2007. (Pubitemid 47583908)
6. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A and Cohen RB: Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25: 1390-1395, 2007. (Pubitemid 46706887)
7. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D and Ludwig DL: IMC-a12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13: 5549-5555, 2007.
8. Hill M and Goldspink G: Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol 549: 409-418, 2003. (Pubitemid 36701754)
9. Li-ling T, Yuan-liang W and Cai-Xin S: The stress reaction and its molecular events: splicing variants. Biochem Biophy Res Comm 320(2): 287-291, 2004.
10. Okazaki R, Durham SK, Riggs BL and Conver CA: Transforming growth factor and forskolin increase all classes of insulin-like growth factor-1 transcripts in normal and human osteoblast-like cells. Biochem Biophys Res Commun 207: 963-970, 1995.
11. Bloor CA, Knight RA, Kedia, RK, Spiteri MA and Allen JT: Differential mRNA expression of insulin-like growth factor-1 splice variants in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med 164(2): 265-272, 2001. (Pubitemid 34001293)
12. Chew SL, Lavender P, Clark AJL and Ross RJM: An alternatively spliced human IGF-1 transcript (IGF-1Ec) with hepatic tissue expression that diverts away from the mitogenic IBE1 peptide. Endocrinology 136: 1939-1944, 1995.
13. Sandberg-Nordqvist AC, Stahlbom PA and Reinecke M: Characterization of insulin-like growth factor-I in human primary brain tumors. Cancer Res 53: 2475-2478, 1993.
14. Shavlakadze T, Rosenthal NA, Wynn N and Grounds MD: Reconciling data from transgenic mice that overexpress IGF-1 specifically in skeletal muscle. Growth Horm IGF Res 15: 4-18, 2005. (Pubitemid 40220850)
15. Cheema U, Brown R, Mudera V, Yang SY, McGrouther G and Goldspink G: Mechanical signals and IGF-1 gene splicing in vitro in relation to development of skeletal muscle. J Cell Physiol 202(1): 67-75, 2005. (Pubitemid 39603363)
16. Philippou A, Papageorgiou E, Bogdanis G, Halapas A, Sourla A, Maridaki M, Pissimissis N and Koutsilieris M: Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: Characterization of the MGF E peptide actions in vitro. In Vivo 23(4): 567-575, 2009.
17. Stavropoulou A, Halapas A, Sourla A, Philippou A, Papageorgiou E, Papalois A and Koutsilieris M: IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro. Mol Med 15(5-6): 127-135, 2009.
18. Stavropoulou A, Philippou A, Halapas A, Sourla A, Pissimissis N, Koutsilieris M: uPA, uPAR and TGFβ1 Expression during early and late post myocardial infarction period in rat myocardium. In Vivo 24(5): 647-652, 2010.
19. Milingos DS, Philippou A, Armakolas A, Papageorgiou E, Sourla A, Protopapas A, Liapi A, Antsaklis A, Mastrominas M and Koutsilieris M: Insulin-like growth factor-1Ec (MGF) expression in eutopic and ectopic endometrium: characterization of the MGF E peptide actions in vitro. Mol Med 17(1-2): 21-28, 2011.
20. Armakolas A, Philippou A, Panteleakou Z, Nezos A, Sourla A, Petraki C, Koutsilieris M: Preferential expression of IGF-1Ec (MGF) transcript in cancerous tissues of human prostate: evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells. Prostate 70(11): 1233-1242, 2010.
21. Koutsilieris M, Rabbani SA, Bennett HP and Goltzman D: Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Invest 80: 941-946, 1987. (Pubitemid 18075626)
22. Boulanger J, Reyes-Moreno C and Koutsilieris M: Mediation of glucocorticoid receptor function by the activation of latent transforming growth factor beta 1 in MG-63 human osteosarcoma cells. Int J Cancer 61(5): 692-697, 1995.
23. Philippou A, Stavropoulou A, Sourla A, Pissimissis N, Halapas A, Maridaki M and Koutsilieris M: Characterization of a rabbit antihuman mechano growth factor (MGF) polyclonal antibody against the last 24 amino acids of the E domain. In Vivo 22: 27-35, 2008.
24. Moschos MM, Armakolas A, Philippou A, Pissimissis N, Panteleakou Z, Nezos A, Kaparelou M and Koutsilieris M: Expression of the insulin-like growth factor 1 (IGF-1) and type I IGF receptor mRNAs in human HLE-B3 lens epithelial cells. In Vivo 25(2): 179-184, 2011.
25. Hingorani P and Kolb EA: Past, present and future of therapies in pediatric sarcomas. Future Oncol 6: 605-618, 2010.
26. Osborne R: Commercial interest waxes for IGF-1 blockers. Nat Biotechnol 26: 719-720, 2008.
27. Kappel CC, Velez-Yanguas MC, Hirschfeld S and Helman LJ: Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 54: 2803-2807, 1994. (Pubitemid 24173778)
28. Sekyi-Otu A, Bell RS, Ohashi C, Pollak M and Andrulis IL: Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Res 55: 129-134, 1995.
29. Kob EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, Houghton P and Gorlick R: R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 55(1): 67-75, 2010.
30. Janeway KA and Grier HE: Sequelae of osteosarcoma medical therapy: A review of rare acute toxicities and late effects. Lancet Oncol 11(7): 670-678, 2010.
31. Longhi A, Errani C, De Paolis M, Mercuri M and Bacci G: Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev 32: 423-436, 2006. (Pubitemid 44309249)
32. Dong J, Demarest SJ, Sereno A, Tamraz S, Langley E, Doern A, Snipas T, Perron K, Joseph I, Glaser SM, Ho SN, Reff ME and Hariharan K: Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther 9: 2593-2604, 2010.
33. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL and Houghton PJ: The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 69(19): 7662-7671, 2009.
34. Dorfman HD and Czerniak B: Bone cancers. Cancer 75: 203-210, 1995.
35. Levi N: Incidence of osteosarcoma, chondrosarcoma and Ewing's sarcoma in east Denmark: Reverse male to female ratio in osteosarcoma. Eur J Orthop Surg Traumatol 8: 147-148, 1998.